DOCSLIB.ORG

Intraprostatic Testosterone and Dihydrotestosterone. Part II

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intraprostatic Testosterone and Dihydrotestosterone. Part II Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer BJUIBJU INTERNATIONAL Tim M. van der Sluis , Eric J.H. Meuleman , R. Jeroen A. van Moorselaar , Hong N. Bui * , Marinus A. Blankenstein * , Annemieke C. Heijboer * and Andr é N. Vis Departments of Urology and * Clinical Chemistry, VU University Medical Centre, Amsterdam, The Netherlands Accepted for publication 26 July 2011 Androgen deprivation therapy (ADT) and What ’ s known on the subject? and What does the study add? 5- α -reductase (5AR) inhibition are used in The male steroid hormone metabolism is an important target in the treatment of the treatment of men with advanced or prostatic diseases. However, present literature is inconsistent about intraprostatic metastatic prostate cancer and benign concentrations of steroid hormones and the role of intraprostatic steroid hormones in prostatic hyperplasia (BPH), respectively. the arise and the course of prostatic diseases is yet to be determined. These drugs exert their effect by lowering androgen levels in the serum and allegedly, Part II of this two-piece mini-review reviews the effect of medication that alters the the prostate gland. It is, however, unknown male steroid hormone metabolism (i.e. 5-alpha reductase inhibitors, androgen whether (increased) intraprostatic androgen deprivation therapy) on intraprostatic steroid hormone concentrations. Better levels are associated with the pathogenesis knowledge of the intraprostatic steroid hormone concentrations might lead to more of BPH and with the initiation and individualized treatment and even to new medical targets. progression of prostate cancer. Also, it is unclear whether intraprostatic treated with ADT for hormone-naive treatment that is tailored to the needs of dihydrotestosterone (DHT) levels correlate prostate cancer, and of those with the individual patient, and probably to new with a response to initial hormonal therapy castration-resistant prostate cancer are all therapeutic targets as well. or with patient outcome. These altered in an equivalent manner because of uncertainties have resulted from the hormonal manipulation. Increased KEYWORDS fi nding that serum testosterone levels do knowledge of the mechanisms of the not necessarily refl ect those in the prostate androgenic steroid pathways in prostatic prostate , prostate cancer , fi nasteride , gland. Intraprostatic DHT levels of men diseases, with a special focus on dutasteride , testosterone , being treated with 5AR inhibition, of those intraprostatic androgen levels, may lead to dihydrotestosterone , androgen treatment INTRODUCTION DHT, 5-alpha-reductase (5AR). Multiple men who receive treatment that is known to randomized studies initiated in the 1980s on interfere with the hypothalamic-pitituary- It has long been recognized that androgenic 5AR inhibition in men with BPH showed a gonadal axis, e.g. ADT and 5AR-inhibition. activity is a major mediator of biological reduction of prostate volume, improvement Knowledge of the levels of intraprostatic processes in the prostate. Early studies from in symptoms and peak urinary fl ow, and a androgens before and after hormonal the 1940s onwards reported that androgen reduction of the risk of acute urinary manipulation might give more insight into deprivation therapy (ADT), by oestrogens retention and BPH-related surgery. In these the bio-availability of intraprostatic (diethylstilbestrol [ DES ] ) or by surgical men, clinical benefi ts were obtained without androgens, and into the cellular mechanisms castration, was able to lower serum lowering testosterone levels in the systemic that lead to the success of or the resistance testosterone levels resulting in a marked circulation. to drug-initiated treatments. biochemical and clinical response in men with metastasized prostate cancer. Currently, In Part I of the present review on ADT by LHRH-agonist treatment or by intraprostatic testosterone and DHT 5AR INHIBITION bilateral orchidectomy is the standard assessment, the levels of the most powerful treatment in those with advanced or biologically active androgens are outlined in ANDROGEN LEVELS AND 5AR INHIBITION disseminated disease [ 1,2 ] . The fi nding that the normal adult prostate, in untreated BPH, IN BPH dihydrotestosterone (DHT) is the major and in prostate cancer. androgen in the prostate led to the McConnell et al . [ 3 ] reported on 69 men development of drugs that block the enzyme Part II of the present review gives an with BPH, who were scheduled for TURP, to that is known to convert testosterone to overview of intraprostatic androgen levels in determine the effect of fi nasteride, a © 2011 THE AUTHORS BJU INTERNATIONAL © 2011 BJU INTERNATIONAL | 109, 183–188 | doi:10.1111/j.1464-410X.2011.10652.x 183 VAN DER SLUIS ET AL. TABLE 1 Testosterone and DHT concentrations after 5AR inhibition Tissue, Method of Tissue DHT, testosterone, Authors n Year Pathology determination 5AR inhibition ng/g tissue ng/g tissue McConnell et al . [ 3 ] 69 1992 BPH RIA Placebo 2.97 0.2 Finasteride 1 mg 0.4 § 1.25 § Finasteride 100 mg 0.14 § 1.69 § Norman et al . [ 4 ] 10 1993 BPH RIA Placebo 5.39 0.32 9 Finasteride 1 mg 1.1 § 2.2 § 8 Finasteride 5 mg 0.49 § 2.4 § Span et al . [ 5 ] 7 1999 BPH RIA Placebo 4.38 0.53 13 Finasteride 5 mg 1.39 § 2.81 § Geller et al . [ 6 ] 10 1990 BPH RIA Baseline 4.5 0.17 Finasteride 5 mg 0.30 § 1.18 § Hill et al . [ 7 ] 15 1996 BPH RIA Placebo 3.54 0.92 6 Finasteride 5 mg 0.68 § 1.96 § Marks et al . [ 8 ] 15 2001 BPH RIA Placebo 4.9 1.5 7 Finasteride 1.0 § 3.6 § Habib et al . * [ 9 ] 9 1997 BPH RIA Placebo 26.6 30.8 19 Finasteride 5 mg 22.9 58.5 § Andriole et al . † [ 10 ] 18 2004 BPH GC-MS Placebo 6.18 0.12 16 Dutasteride 0.17 § 0.25 § 5/10 mg Wurzel et al . † [ 12 ] 21 2007 BPH LC-MS Placebo 3.23 0.092 22 Dutasteride 0.5 mg 0.21 § 2.54 § Rittmaster et al . † [ 11 ] 21 2008 BPH + Prostate GC-MS/LC-MS Placebo 3.37 ‡ 0.17 cancer ‡ Dutasteride 0.5 mg – – 72 2 weeks 0.55 § 1.72 § 71 1 month 0.33 § 1.91 § 22 3 months 0.26 § 2.80 § 25 4 months 0.23 § 3.40 § Gleave et al . † [ 13 ] 14 2006 Prostate cancer GC-MS Placebo 3.3 0.07 14 Dutasteride 0.5 mg 0.23 § 3.4 § 13 Dutasteride 3.5 mg 0.039 § 2.8 § * Measurement in dry weight. † Similar study group. ‡ Pooled data of BPH and prostate cancer patients. § Statistically signifi cant difference against baseline. Placebo = placebo tablet or ‘ no therapy ’ . Testosterone: 1 nmol/L = 28.8 ng/dL; 1 ng = 0.00347 nmol. DHT: 1 nmol/L = 29.0 ng/dL; 1 ng = 0.00344 nmol. 5ARI, 5AR inhibitor; RIA, radioimmunoassay; LC, liquid-chromatography mass spectrometry; GC, gas-chromatography mass spectrometry. 5AR-type-2 inhibitor, on clinical outcome, Norman et al . [ 4 ] studied 27 men who were Similar decreases in intraprostatic DHT side-effects and (intraprostatic) androgen scheduled for TURP for BPH and who were levels, and reciprocal rises of prostatic levels. Patients were treated with placebo or randomized between placebo ( n = 10), and testosterone levels after fi nasteride 1, 5, 10, 50 or 100 mg fi nasteride for 7 days 6 – 8 weeks pretreatment with 1 mg treatment up to 100 mg/day have been before surgery. In the placebo group, the fi nasteride ( n = 9), or 5 mg fi nasteride ( n = reported by other study groups [ 5 – 8 ] ; mean prostatic DHT level was 2.97 ng/g 8). Tissue DHT levels in the placebo group however, Habib et al . [ 9 ] , in their randomized tissue, and the mean tissue testosterone were 5.39 ng/g tissue, and decreased to study on intraprostatic androgen levels on level was 0.2 ng/g tissue ( Table 1 [ 3 – 13 ] ). 1.1 ng/g tissue for 1 mg fi nasteride, and 5AR treatment, were unable to show a There was an incremental increase of 0.49 ng/g tissue for 5 mg fi nasteride ( P = signifi cant difference in testosterone and intraprostatic testosterone level and a 0.049 between doses). Intraprostatic DHT levels between the fi nasteride and reciprocal decrease of intraprostatic DHT testosterone levels in the placebo group placebo-treated group. level with higher dosages of fi nasteride. All increased from 0.32 ng/g tissue to 2.2 ng/g treatment groups were signifi cantly different tissue with 1 mg fi nasteride and 2.4 ng/g Rittmaster et al . [ 10 ] published a study on from the placebo group, but not different tissue with 5 mg fi nasteride ( P = intraprostatic androgen levels in men with from each other. nonsignifi cant between doses). BPH who were scheduled for TURP [ 10 – 12 ] . © 2011 THE AUTHORS 184 BJU INTERNATIONAL © 2011 BJU INTERNATIONAL INTRAPROSTATIC ANDROGEN LEVELS AFTER ANDROGEN HORMONAL MANIPULATION Patients were randomized between surgery palmetto. Similar observations were made by by 80% after 1 month of LHRH antagonist alone and placebo or neoadjuvant Di Silverio et al . [ 14 ] . treatment and that intraprostatic androgen dutasteride, a dual 5AR-type-1 and -2 levels were not suppressed to the same inhibitor, 0.5 mg or 3.5 mg. After 4 months degree as serum androgen levels. of drug treatment, the mean intraprostatic ADT DHT level was suppressed by 93.1% for 0.5 mg dutasteride and by 98.9% for 3.5 mg ANDROGEN LEVELS AND ADT IN BPH ANDROGEN LEVELS AND ADT IN PROSTATE dutasteride (both P < 0.001 versus placebo). CANCER For testosterone, intraprostatic values were Various types of ADT, alone or in signifi cantly greater in subjects who combination, were compared for their effect Multiple studies have shown that relatively received dutasteride 0.5 mg or 3.5 mg on intraprostatic DHT concentration in large amounts of DHT exist in prostate versus the surgery-alone group ( P < 0.001).
Load more

Recommended publications
  • Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?
    Physiol. Res. 52: 397-407, 2003 MINIREVIEW Dehydroepiandrosterone – Is the Fountain of Youth Drying Out? P. CELEC 1,2, L. STÁRKA3 1Faculty of Medicine, 2Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia and 3Institute of Endocrinology, Prague, Czech Republic Received September 15, 2002 Accepted October 7, 2002 Summary Dehydroepiandrosterone (DHEA) and its sulphate-bound form (DHEAS) are important steroids mainly of adrenal origin. Their physiological and pathophysiological functions are not yet fully identified, although a number of various possible features have been hypothesized. Most popular is the description of the “hormone of youth” as the long-term dynamics of DHEA levels are characterized by a sharp age-related decline in the late adulthood and later. Low levels of DHEA are, however, associated not only with the ageing process but also with diabetes mellitus, cardiovascular diseases and some neurological or immunological entities. In the past decade, a number of brief studies have concentrated on these relationships and also on the role of exogenous DHEA in health, disease and human well-being. This article tries to summarize some of the most important facts achieved recently. Key words Dehydroepiandrosterone • Intracrinology • Hormone replacement therapy • Steroids Introduction functions: 1) DHEA is an endogenous metabolite that cannot be patented so that pharmaceutical companies are In 1934 Butenandt and Dannenbaum isolated not interested in supporting research in this field. dehydroepiandrosterone (DHEA) from urine and in 1944 2) DHEA can be described as a “human molecule” Munson and colleagues identified its 3β-sulphate because other investigated species have much lower (DHEAS). Even now, nearly 70 years later, we still do concentrations.
    [Show full text]
  • Androgens Utilization Management Criteria
    ANDROGENS UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Androgens Generic (Brand) NAMES: • Fluoxymesterone (Androxy®) • Methyltestosterone (Android®, Methitest®, Testred®) • Testosterone, topical A. Androderm®, Androgel® - Preferred topical testosterone ® ® ® ™ B. Testim , Fortesta , Axiron , Bio-T-Gel • Testosterone, buccal (Striant®) • Testosterone cypionate (e.g., Depo-Testosterone®) • Testosterone enanthate (e.g., Delatestryl®) FDA-APPROVED INDICATIONS: Replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. Hypogonadotropic hypogonadism (congenital or acquired): Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty: To stimulate puberty in carefully selected males with clearly delayed puberty. Metastatic mammary cancer in women: Used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal COVERAGE AUTHORIZATION CRITERIA for the androgen products listed above: 1. Being used for ONE of the following: a. Males for the treatment of hypogonadism (low testosterone): i. patient has symptoms of androgen deficiency AND ii. has a baseline (pre-treatment) morning serum total testosterone level of less than or equal to 300 ng/dL or a serum total testosterone level that is below the testing laboratory’s lower limit of the normal range OR iii. baseline morning serum free testosterone level, measured by the equilibrium dialysis method, of less than or equal to 50 pg/ml or a free serum testosterone level that is below the testing laboratory’s lower limit of the normal range, OR b.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis
    ORIGINAL ARTICLE Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis Ana E. Espinosa De Ycaza, Robert A. Rizza, K. Sreekumaran Nair, and Michael D. Jensen Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905 Downloaded from https://academic.oup.com/jcem/article/101/4/1719/2804555 by guest on 24 September 2021 Context: Dehydroepiandrosterone (DHEA) and T hormones are advertised as antiaging, antiobe- sity products. However, the evidence that these hormones have beneficial effects on adipose tissue metabolism is limited. Objective: The objective of the study was to determine the effect of DHEA and T supplementation on systemic lipolysis during a mixed-meal tolerance test (MMTT) and an iv glucose tolerance test (IVGTT). Design: This was a 2-year randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at a general clinical research center. Participants: Sixty elderly women with low DHEA concentrations and 92 elderly men with low DHEA and bioavailable T concentrations participated in the study. Interventions: Elderly women received 50 mg DHEA (n ϭ 30) or placebo (n ϭ 30). Elderly men received 75 mg DHEA (n ϭ 30),5mgT(nϭ 30), or placebo (n ϭ 32). Main Outcome Measures: In vivo measures of systemic lipolysis (palmitate rate of appearance) during a MMTT or IVGTT. Results: At baseline there was no difference in insulin suppression of lipolysis measured during MMTT and IVGTT between the treatment groups and placebo. For both sexes, a univariate analysis showed no difference in changes in systemic lipolysis during the MMTT or IVGTT in the DHEA group and T group when compared with placebo.
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • Gender-Affirming Hormone Therapy
    GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical
    [Show full text]
  • Adverse Effects of Anabolic-Androgenic Steroids: a Literature Review
    healthcare Review Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review Giuseppe Davide Albano 1,†, Francesco Amico 1,†, Giuseppe Cocimano 1, Aldo Liberto 1, Francesca Maglietta 2, Massimiliano Esposito 1, Giuseppe Li Rosi 3, Nunzio Di Nunno 4, Monica Salerno 1,‡ and Angelo Montana 1,*,‡ 1 Legal Medicine, Department of Medical, Surgical and Advanced Technologies, “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy; [email protected] (G.D.A.); [email protected] (F.A.); [email protected] (G.C.); [email protected] (A.L.); [email protected] (M.E.); [email protected] (M.S.) 2 Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; [email protected] 3 Department of Law, Criminology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy; [email protected] 4 Department of History, Society and Studies on Humanity, University of Salento, 73100 Lecce, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-095-3782153 † These authors contributed equally to this work. ‡ These authors share last authorship. Abstract: Anabolic-androgenic steroids (AASs) are a large group of molecules including endoge- nously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes’ performance, minimizing androgenic effects. AAS use is very popular and 1–3% of US inhabitants have been estimated to be AAS users. However, AASs have side effects, involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system Citation: Albano, G.D.; Amico, F.; and the reproductive system, thereby, their abuse is considered a public health issue.
    [Show full text]
  • Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and Is a Therapeutic Target for Advanced Prostate Cancer
    Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer Cameron M. Armstrong1*, Chengfei Liu1*, Liangren Liu1,2*, Joy C. Yang1, Wei Lou1, Ruining Zhao1,3, Shu Ning1, Alan P. Lombard1, Jinge Zhao1, Leandro S D'Abronzo1, Christopher P. Evans1,4, Pui-Kai Li5, Allen C. Gao1, 4, 6,7 Running title: Targeting steroid sulfatase for advanced prostate cancer Key words: Prostate cancer, steroid sulfatase, resistance, intracrine androgen synthesis, adrenal androgens 1Department of Urologic Surgery, University of California Davis, CA, USA 2Present address: Department of Urology, West China Hospital, Sichuan University, China 3Present address: Department of Urology, General Hospital of Ningxia Medical University, China 4UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA 5Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA 6VA Northern California Health Care System, Sacramento, CA, USA 7Corresponding author: Allen Gao, University of California Davis, 4645 2nd Avenue, Sacramento, CA 95817, USA. Phone: 916-734-8718, email: [email protected] *These authors contributed equally to the work. Conflict of interest: PKL and ACG are co-inventors of a patent application of the selected small molecule inhibitors of steroid sulfatase. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]